First in human phase I study of copanlisib (BAY 80 6946) an intravenous pan class I phosphatidylinositol 3 kinase inhibitor, in patients with advanced solid tumors and non Hodgkin's lymphomas
This phase I study evaluated the safety, tolerability, and pharmacokinetics of copanlisib, an intravenously administered pan phosphatidylinositol 3 kinase inhibitor in patients with advanced solid tumors or non Hodgkin's lymphoma. Copanlisib was well tolerated with a manageable safety profile, with anti tumor activity in both advanced solid tumors and hematological malignancies.
Annals of oncology official journal of the European Society for Medical Oncology